Muscle-eye-brain disease is a congenital muscular dystrophy characterized by structural brain and eye defects. Here, we describe a 12-year-old boy with partial agenesis of corpus callosum, ventriculomegaly, flattened brain stem, diffuse pachygyria, blindness, profound cognitive deficiencies, and generalized muscle weakness, yet without a clear dystrophic pattern on muscle biopsy. There was no glycosylation of a-dystroglycan and the genetic screening revealed a novel truncating mutation, c.1545delC (p.Tyr516Thrfs*21), and a previously identified missense mutation, c.1469G>A (p.Cys490Tyr), in the protein O-mannose beta-1,2-N-acetylglucosaminyltransferase 1 (POMGNT1) gene. These findings broaden the clinical spectrum of muscle-eye-brain disease to include pronounced hypotonia with severe brain and eye malformations, yet with mild histopathologic changes in the muscle specimen, despite the absence of glycosylated a-dystroglycan.
Muscle-eye-brain disease (MIM 253280) belongs to a group of rare muscular dystrophies with autosomal recessive inheritance known as dystroglycanopathies. 1 These diseases have a wide clinical spectrum, ranging from congenital muscular dystrophy associated with severe brain and eye malformation (Walker Warburg syndrome [MIM 236670], muscle-eye-brain disease and Fukuyama congenital muscular dystrophy [MIM 253800]) 2, 3 to mild forms of muscle weakness with later onset and without brain involvement (limb-girdle muscular dystrophy type 2O [MIM 613157]). 4, 5 Muscle-eye-brain disease patients usually present muscle weakness and hypotonia at or soon after birth, and only some patients acquire independent ambulation. The most common cerebral and ocular features are pachygyria-type cortical neuronal migration disorder with hypoplasia of the brain stem and cerebellum, severe myopia, cataracts, and retinal hypoplasia. Severe mental retardation and epilepsy are also constant clinical features. 1 It is known that aberrant O-glycosylation of a-dystroglycan (a-DG) underlies the pathogenesis of these diseases because the interaction between a-DG and extracellular matrix proteins is mediated by O-linked glycans. This protein is the central component of the dystrophin-glycoprotein complex, and one of the best known O-mannosyl glycosylated proteins. 6 There are 2 main O-mannosyl glycans on the mucin-like domain of a-DG that are critical for ligand-binding activity. The first O-mannosyl glycan of a-DG, Neu5Aca3Galb4GlcNAcb2-Man-O-Ser/Thr, was described by Chiba et al 7 for bovine peripheral nerve. Recently, a novel phosphorylated O-mannosyl glycan required for laminin binding was identified on recombinant a-DG. 8 Muscle-eye-brain disease is caused almost exclusively by mutations in the gene encoding the POMGNT1 glycosyltransferase (protein O-mannose beta-1,2-N-acetylglucosaminyltrans ferase 1), which catalyzes the transfer of N-acetylglucosamine to O-mannose residues. 9 The clinical phenotype of muscle-eye-brain disease is heterogeneous, ranging from severe brain, eye, and muscle anomalies to mild brain and muscle defects accompanied by severe ocular deficits. 10 Here we describe the clinical, histopathologic, and molecular genetic characterization of an unusual muscle-eye-brain disease patient with severe neurologic and ocular abnormalities, yet with minimal myopathologic changes. Immunohistologic examination revealed a hypoglycosylated a-DG with a highly reduced laminin-binding ability. The POMGNT1 gene of this patient suffered a novel frameshift mutation, giving rise to a truncated protein. These findings highlight the wide clinical spectrum of muscle-eye-brain disease and further emphasize the role of the POMGNT1 gene as the worldwide predominant cause of muscle-eye-brain disease.
Methods Patient
A patient with muscle-eye-brain disease that was associated with abnormal a-DG glycosylation, as witnessed in a muscle biopsy, was studied.
Histologic Analysis and Immunohistochemistry
Two biopsies of the quadriceps muscle were performed (at 6 and 12 mo of age) and analyzed by classical histology and immunohistochemistry. Ten-micrometer-thick cryosections of muscle specimens from the patient and a control individual were stained with hematoxylin and eosin 11 and mouse monoclonal antibodies against different glycan epitopes of a-DG (VIA4, Millipore Corporation, Billerica, MA) and b-DG (Novocastra, Newcastle-on-Tyne, UK) as described previously. 12 Also, antibodies against dystrophin (DYS 1, 2 and 3), spectrin (both from Novocastra), and laminin-a2 (MAB1922, Chemicon, Millipore Corporation) were used.
Immunoblot Analysis and Laminin Overlay Assay
Total protein extracts were obtained from frozen tissue samples and resolved by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) (7% for a-DG and 10% for b-DG) following the procedures described previously. 13 For laminin overlay assay, the polyvinylidene diflouride membrane was blocked using a laminin-binding buffer (10 mM triethanolamine, 140 mM NaCl, 1 mM MgCl 2 , and 1 mM CaCl 2 , pH 7.6) containing 5% nonfat dry milk and incubated overnight with merosin (Sigma Aldrich, St Louis, MO) at 4 C in the lamininbinding buffer. The membrane was then washed and incubated with anti-laminin antibody (Sigma Aldrich) followed by horseradish peroxidase conjugated anti-rabbit IgG (Santa Cruz Biotechnology Inc, Santa Cruz, CA) and the bound proteins were visualized by chemiluminescence (ECL Plus, GE Healthcare, United Kingdom).
Mutation Analysis
Genomic DNA from the patient and his parents was isolated from total blood samples using standard techniques. The coding exons, flanking intronic regions and polyadenylation sites of the POMT1, POMT2, POMGNT1, FKTN, FKRP, LARGE, and DAG1 genes, were screened. A 5 0 -upstream region of approximately 650 bp (promoter region) was also screened for each gene. Polymerase chain reactions were performed using BIOTAQ TM deoxyribonucleic acid polymerase (Bioline, London, United Kingdom) and specific primers available under request.
Results

Clinical Findings
This 12-year-old boy was the first child of nonconsanguineous parents and there were no noteworthy features in his family medical history. An ultrasonographic scan in the third trimester revealed ventricular enlargement associated with midline anomalies, and a brain malformation was suspected. The child was born at term without any complications, weighing 2700 g and with an Apgar score of 8/9. From birth, he exhibited marked axial and appendicular hypotonia with generalized muscle weakness and fixed knee flexion contractures, although no breathing or feeding difficulties were observed. He showed global hyporeflexia. The baby had poor visual alertness and abnormal eye movements. A neonatal ophthalmologic examination revealed the persistence of the hyaloid artery and anomalous choroidal vascularization with retinal dysplasia. Biochemical evaluation demonstrated moderate elevation of serum creatine kinase levels (857 units/L: normal <175 units/ L). The child had a normal 46, XY karyotype. Cranial magnetic resonance imaging (MRI) revealed partial absence of the corpus callosum, with ventriculomegaly and colpocephaly. There was also flattening of the brain stem, and diffuse pachygyria predominantly affected the frontal lobes ( Figures 1A and B) .
In a follow-up examination, the patient exhibited severe global developmental delay, and the axial and limb weakness persisted although the initial hypotonia gave rise to appendicular spasticity by age 3. The child's ocular problems were exacerbated by bilateral glaucoma and cataracts. Creatine kinase levels reached 3000 units/L. A new cranial MRI (at age 5) revealed periventricular white matter hyperintensities in T2 and fluid-attenuated inversion recovery sequences, in addition to the previous observations. At 7 years of age, the patient had a generalized tonic-clonic seizure while sleeping. Conventional electroencephalography revealed background slowing, with slow waves in the temporo-occipital lobe of the left cerebral hemisphere. On examination at age 12, the patient was blind and suffered profound cognitive deficiencies, with no verbal language, and he only reacted to tactile stimuli. He had spastic tetraplegia with hyperreflexia 3þ in the bilateral knees and Achilles tendon as well as fixed contractures with equinovarus foot. Moreover, he had not acquired unsupported sitting and his head control was incomplete.
At that age, the family declined to perform any further muscular studies.
Histologic Analysis and Immunohistochemistry
Two biopsies of the quadriceps muscle were performed at 6 ( Figure 1D ) and 12 months of age ( Figure 1E ) and analyzed by classical histology and immunohistochemistry. In both cases histologic examination revealed mild myopathic changes with variation in fiber size and the presence of hypercontracted fibers. The muscle architecture was preserved without endomysial fibrosis or fat tissue replacement. There were no necrotic or regenerating fibers. The diameter of the fibers varied generally between 10 and 50 mm. Muscle cryosections were stained for myofibrillar adenosine triphosphatase (ATPase) at pH 4.3 (Figure 1G) , showing a slight predominance of type II fibers, and the atrophic fibers were mostly type II. There were no obvious intermediate stain-type 2C fibers.
However, when the glycosylation state of a-DG was evaluated by immunohistochemistry, there was no staining in the muscle biopsy revealed with the VIA4 antibody ( Figure 1I ), whereas immunostaining with anti-b-DG antibody showed positive membrane staining ( Figure 1K ). Merosin, dystrophin, and b-spectrin immunostaining was normal (data not shown).
Immunoblot Analysis and Laminin Overlay Assay
The absence of functionally glycosylated a-DG was confirmed in immunoblots probed with the VIA4 antibody and this result was corroborated in a laminin overlay assay that revealed no detectable laminin binding ( Figure 1L ).
Mutation Analysis
DNA sequencing revealed 2 heterozygous mutations in the POMGNT1 gene. One mutation was a novel 1-bp deletion in exon 18, c.1545delC (p.Tyr516Thrfs*21), which led to a frameshift and created a premature stop codon at amino acid 536 (Figure 2A, right panel) . This alteration was absent in 200 healthy control individuals. Sequence analysis of the corresponding exons in the parents' POMGNT1 gene confirmed that this mutation was inherited from his father. The second mutation was a previously reported missense mutation located in exon 17, c.1496G>A (p.Cys490Tyr), which was carried by the patient's mother (Figure 2A, left panel) .
Discussion
The Spanish muscle-eye-brain disease patient described here presented a combination of severe ocular and cerebral malformations associated with marked hypotonia, muscle weakness, and elevated serum creatine kinase levels but with almost normal muscle histology.
From birth, he exhibited hypotonia with generalized muscle weakness and severe global developmental delay. Functional capacity was limited as the patient was unable to acquire a sitting position or maintain head control unaided. These are common features of severe muscle-eye-brain disease, whereas motor abilities can be acquired in mild muscle-eye-brain disease presentations. 14 Histologic examination of the patient's muscle revealed only mild myopathic changes and minimal variation in muscle fiber diameter, somewhat surprising given the pronounced phenotypic severity exhibited by the patient. Muscular dystrophy is present in all dystroglycanopathy patients, as reflected by biochemical parameters such as elevated serum creatine kinase levels and the appearance of necrosis, fibrosis, and regenerative fibers in muscle biopsies. 15 It has been described that in muscle-eye-brain disease, dystrophic changes develop more slowly and become evident with increasing age. However, necrotic and regenerative fibers are a common feature at infancy (0-5 y), and architectural changes, such as fat infiltration, become evident during later years. 16 In contrast, our patient did not present necrotic and regenerating fibers at 1 year of age. It was not possible to monitor the progress of myopathologic changes beyond 1 year of age because a muscle biopsy is invasive for the patient and a repetitive extraction is not always feasible.
Also, mild dystrophic changes have been described in mild muscle-eye-brain disease patients with increased functional capacity that achieve independent ambulation. 14 It is intriguing that despite severe brain and eye anomalies exhibited by the patient, only mild muscle histopathologic alterations with absent glycosylated a-DG were found. The absence of the glycosylated form of a-DG was consistent with the correlation between the loss of a-DG glycosylation and the severity of the phenotype in patients carrying mutations in POMT1, POMT2, and POMGNT1. 17 Our observations also confirm the correlation between the hypoglycosylation of a-DG and motor ability, whereby glycosylated a-DG is not detected in patients who never acquire an independent sitting position and there is stronger a-DG staining in individuals who achieve independent ambulation than in those who never walk. 18 The patient carried a novel heterozygous mutation in the POMGNT1 gene, c.1545delC (p.Tyr516Thrfs*21), which generates a frameshift and an early stop codon and results in the deletion of 125 amino acids within the catalytic domain. The second mutation, c.1469G>A (p.Cys490Tyr), has been described previously in several dystroglycanopathy patients and in a few fetal cobblestone lissencephaly cases. 10, [19] [20] [21] The 2 mutations affect residues spanning the catalytic domain of POMGNT1 ( Figure 2B ). Although the novel mutation p.Tyr516Thrfs*21 gives rise to a truncated protein, the Cys 490 residue, which according to the crystal structure of GnTI (N-acetylglucosaminyltransferase I) forms a cysteine bridge with Cys 421, is critical for the catalytic activity of POMGNT1. Indeed, the recent biochemical characterization of various POMGNT1 mutants containing Cys490Tyr mutation and nonsense mutations affecting residues within the catalytic domain such as Trp590X and Arg580X revealed no enzymatic activity, which allows postulating that the 2 alterations reported can strongly impair the enzyme activity. 22 We have characterized a severe dystroglycanopathy patient with brain and eye abnormalities typical of muscle-eye-brain disease but with very mild histologic muscular changes. Severe muscle weakness, hypotonia, and elevated serum creatine kinase levels were detected, along with the absence of glycosylated a-DG. Our findings broaden the clinical spectrum of muscleeye-brain disease and suggest that analysis of POMGNT1 gene mutations can be useful in patients with severe structural brain and ocular defects, mental retardation, and congenital hypotonia, independent of the severity of the dystrophic pattern in skeletal muscle. Given the overlapping clinical spectra of dystroglycanopathy patients, further understanding of the different phenotypes of muscle-eye-brain disease and other dystroglycanopathies will aid the establishment of gene priority in genetic analysis of these patients.
